Ananya Health

Ananya Health identified a critical gap in cervical cancer prevention infrastructure. While screening tests could detect precancerous lesions in resource-limited settings, 80% of clinics worldwide lacked the equipment to treat them—forcing patients to travel to distant hospitals or forgo treatment entirely. Women in low-income countries experienced this most acutely, facing both detection and treatment barriers that wealthy nations had already solved. The problem was measurable: cervical cancer remained the fourth-leading cancer killer globally despite being preventable. Existing alternatives were expensive ($50,000+ cryoablation units) or required hospitalization, making them inaccessible in primary care clinics. Early validation came from clinic partnerships in India and Africa, where providers immediately adopted the portable device once available, and from WHO endorsement of cryotherapy as standard-of-care. Patient demand proved the approach worked—clinics reported near-100% treatment completion rates when the device was on-site, versus previous abandonment rates exceeding 60%.

Ananya Health's MVP was a stripped-down cryoablation device that eliminated the refrigeration infrastructure required by existing systems, focusing purely on freezing abnormal cervical cells in resource-limited clinics. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌They shipped their first prototype within eighteen months, deliberately omitting advanced imaging, wireless connectivity, and multi-application capabilities that competitors offered. This constraint forced them to nail a single workflow: detection and immediate treatment in one visit. The execution strategy paid dividends early. Pilot deployments in Indian clinics showed 94% treatment completion rates—validating that simplicity actually improved clinical outcomes by reducing patient dropout. Clinicians reported setup time under five minutes, a stark contrast to hospital-grade alternatives requiring specialized technicians. However, the narrow focus initially limited market expansion; scaling beyond cervical cancer required rebuilding core functionality. Early validation proved their core insight—that removing complexity could democratize access—but their deliberate constraints eventually demanded rearchitecture for broader adoption.